Vertex Pharmaceuticals (europe) Ltd - Net Worth and Insider Trading
Vertex Pharmaceuticals (europe) Ltd Net Worth
The estimated net worth of Vertex Pharmaceuticals (europe) Ltd is at least $273 Million dollars as of 2024-11-13. Vertex Pharmaceuticals (europe) Ltd is the 10% Owner of CRISPR Therapeutics AG and owns about 5,380,940 shares of CRISPR Therapeutics AG (CRSP) stock worth over $273 Million. Details can be seen in Vertex Pharmaceuticals (europe) Ltd's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Vertex Pharmaceuticals (europe) Ltd has not made any transactions after 2018-12-27 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Vertex Pharmaceuticals (europe) Ltd
Vertex Pharmaceuticals (europe) Ltd Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Vertex Pharmaceuticals (europe) Ltd owns 1 companies in total, including CRISPR Therapeutics AG (CRSP) .
Insider Ownership Summary of Vertex Pharmaceuticals (europe) Ltd
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| CRSP | CRISPR Therapeutics AG | 2018-12-27 | 10 percent owner |
Vertex Pharmaceuticals (europe) Ltd Latest Holdings Summary
Vertex Pharmaceuticals (europe) Ltd currently owns a total of 1 stock. Vertex Pharmaceuticals (europe) Ltd owns 5,380,940 shares of CRISPR Therapeutics AG (CRSP) as of December 27, 2018, with a value of $273 Million.
Latest Holdings of Vertex Pharmaceuticals (europe) Ltd
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| CRSP | CRISPR Therapeutics AG | 2018-12-27 | 5,380,940 | 50.73 | 272,975,086 |
Holding Weightings of Vertex Pharmaceuticals (europe) Ltd
Vertex Pharmaceuticals (europe) Ltd Form 4 Trading Tracker
According to the SEC Form 4 filings, Vertex Pharmaceuticals (europe) Ltd has made a total of 0 transactions in CRISPR Therapeutics AG (CRSP) over the past 5 years. The most-recent trade in CRISPR Therapeutics AG is the acquisition of 40,198 shares on December 27, 2018, which cost Vertex Pharmaceuticals (europe) Ltd around $1 Million.
Insider Trading History of Vertex Pharmaceuticals (europe) Ltd
- 1
Vertex Pharmaceuticals (europe) Ltd Trading Performance
GuruFocus tracks the stock performance after each of Vertex Pharmaceuticals (europe) Ltd's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Vertex Pharmaceuticals (europe) Ltd is 37.64%. GuruFocus also compares Vertex Pharmaceuticals (europe) Ltd's trading performance to market benchmark return within the same time period. The performance of stocks bought by Vertex Pharmaceuticals (europe) Ltd within 3 months outperforms 2 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Vertex Pharmaceuticals (europe) Ltd's insider trading performs compared to the benchmark.
Performance of Vertex Pharmaceuticals (europe) Ltd
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 28.97 | | | | | |
| Relative Return to S&P 500(%) | 19.24 | | | | | |
Vertex Pharmaceuticals (europe) Ltd Ownership Network
Ownership Network List of Vertex Pharmaceuticals (europe) Ltd
Ownership Network Relation of Vertex Pharmaceuticals (europe) Ltd
Vertex Pharmaceuticals (europe) Ltd Owned Company Details
What does CRISPR Therapeutics AG do?
Who are the key executives at CRISPR Therapeutics AG?
Vertex Pharmaceuticals (europe) Ltd is the 10 percent owner of CRISPR Therapeutics AG. Other key executives at CRISPR Therapeutics AG include Chief Business Officer Samarth Kulkarni , General Counsel and Secretary James R. Kasinger , and Chief Financial Officer Raju Prasad .
CRISPR Therapeutics AG (CRSP) Insider Trades Summary
Over the past 18 months, Vertex Pharmaceuticals (europe) Ltd made no insider transaction in CRISPR Therapeutics AG (CRSP). Other recent insider transactions involving CRISPR Therapeutics AG (CRSP) include a net sale of 179,630 shares made by Samarth Kulkarni , a net sale of 6,949 shares made by James R. Kasinger , and a net sale of 3,524 shares made by Raju Prasad .
In summary, during the past 3 months, insiders sold 5,382 shares of CRISPR Therapeutics AG (CRSP) in total and bought 0 shares, with a net sale of 5,382 shares. During the past 18 months, 193,469 shares of CRISPR Therapeutics AG (CRSP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 193,469 shares.
CRISPR Therapeutics AG (CRSP)'s detailed insider trading history can be found in Insider Trading Tracker table.
CRISPR Therapeutics AG Insider Transactions
Vertex Pharmaceuticals (europe) Ltd Mailing Address
Above is the net worth, insider trading, and ownership report for Vertex Pharmaceuticals (europe) Ltd. You might contact Vertex Pharmaceuticals (europe) Ltd via mailing address: 2 Kingdom Street, 9th Floor, London X0 W2 6bd.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
